15 Nov 2023 , 11:48 AM
Biocon Biologics, a Biocon subsidiary, stated on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has given marketing authorization for YESAFILI, an Aflibercept biosimilar.
This clearance followed the European Commission’s (EC) permission for marketing authorization in the European Union (EU) in September.
YESAFILI, an ophthalmology product, is intended to treat a variety of eye conditions, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).
The biosimilar is highly comparable to the reference medication Eylea® (aflibercept).
At around 11.44 AM, Biocon was trading 1.21% higher at Rs 230.10, against the previous close of Rs 227.35 on NSE. The counter touched an intraday high and low of Rs 231.75 and Rs 228.45, respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.